Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and whatnot has, of course, returned. But what can you do? The world keeps spinning which, after all, is a good thing. So with this glass-half-full approach in mind, time to fire up the coffee kettle, quaff a cup or three of stimulation, and dig in for another busy day. On that note, here are some tidbits. Hope your journey progresses nicely and, as always, do keep in touch …

Novartis (NVS) is abandoning an effort to gain U.S. regulatory approval for a biosimilar of Rituxan, a Roche (RHHBY) drug to treat certain cancer and rheumatoid arthritis. The decision comes after the Food and Drug Administration sought additional information to support the medicine, which is already approved in the European Union, Switzerland, Japan, and Australia. Rituxan is a monoclonal antibody used in non-Hodgkin’s lymphoma and rheumatoid arthritis; it had more than $4 billion in sales in the U.S. in 2016.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy